Split Thickness Donor Site Healing With MIST Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01214980
Recruitment Status : Completed
First Posted : October 5, 2010
Results First Posted : December 19, 2014
Last Update Posted : December 19, 2014
Information provided by (Responsible Party):
Celleration, Inc.

October 4, 2010
October 5, 2010
December 11, 2014
December 19, 2014
December 19, 2014
February 2012
July 2013   (Final data collection date for primary outcome measure)
Rate of Wound Healing [ Time Frame: Days to absence of drainage from the initial donor site harvest procedure ]
The primary endpoint is an average of the group for each participant's donor site wound closure time, defined as days to absence of drainage from the date of the initial donor site harvest procedure.
Rate of Wound Healing [ Time Frame: 6 weeks ]
The primary endpoint will be determined by the time to wound closure from the date of each subject's initial donor site harvest procedure.
Complete list of historical versions of study NCT01214980 on Archive Site
  • Time to Full Epithelialization [ Time Frame: Days to full epithelialization ]
    Time to full epithelialization in days from the date of initial donor site harvest procedure per the blinded adjudication of the donor site image.
  • Numeric Pain Score [ Time Frame: 5 weeks ]
    Average donor site pain score for each treatment group, numeric scale of 0 (no pain) to 10 (worst possible pain), at five weeks post skin graft procedure
  • Numeric Itching Score [ Time Frame: 5 weeks ]
    Average donor site itching score for treatment group, numeric scale 0 (no itch) to 10 (worst possible itch), at 5 weeks post skin graft procedure
  • Donor Site Recidivism Rate [ Time Frame: 6 weeks ]
    Number of donor sites that healed and then reopened during the study.
Cellular and molecular changes in the wound bed [ Time Frame: 5 days ]
The secondary endpoint will be evaluated by molecular protein analysis including: proinflammatory cytokine mediators, inflammatory chemokine mediators, tissue reparative and remodeling mediators (MMPs and TIMPs)
Not Provided
Not Provided
Split Thickness Donor Site Healing With MIST Study
A Prospective, Randomized, Controlled Pilot Study of the MIST Therapy System for the Treatment of Split Thickness Donor Sites
Subjects requiring skin grafting due to burns, trauma, or chronic venous ulcers with split thickness donor sites expected to be between 20 and 200 square cm will be consecutively screened for study eligibility. This study is a prospective, randomized, controlled trial evaluating effect of MIST Therapy on the healing of split thickness skin graft donor sites compared to standard care. Subjects meeting all eligibility criteria and providing appropriate written informed consent will be enrolled for study participation.

Enrolled subjects will be randomized to receive one of two treatment courses: a) MIST Therapy in conjunction with standard of care (SOC) (treatment group); or b)SOC alone (control group).

On post-op day 1, subjects will undergo a baseline evaluation prior to initiating assigned study treatment, including: wound measurement, wound bed evaluation, description of periwound skin, measurement of type and quantity of exudation, wound clinical symptoms (pain, burning, itching), and digital photography. Subject will then receive assigned study treatment.

SOC includes, but is not limited to, fluid resuscitation, pain medications, systemic antibiotics, control of bleeding, and standard dressings as appropriate for the moisture balance of the wound. SOC also includes providing a hydrocolloid border around the wound with a transparent film dressing over the donor site. No advanced or impregnated dressings are allowed during the study. No topical antibiotics or antibiotic dressings, topical antiseptics (silver, iodine, etc.,) or antimicrobials are allowed.

The transparent film will be removed each day and wound fluid will be collected for analysis. After wound fluid collection, subjects will receive their assigned study treatment. Subjects randomized to receive MIST Therapy will be treated daily for 5 consecutive days. Following administration of the assigned study treatment, subjects will have replacement of the transparent film. The hydrocolloid will remain in place on the border of intact skin.

Evaluations performed will include a wound assessment, digital photography, wound pain assessment and an adverse event assessment. Following the initial 5 day treatment, the study wounds will be dressed per SOC with dressing changes as needed.

Subjects will undergo a weekly wound assessment through 6 weeks from the date of study enrollment. A weekly wound assessment will include the assessment of maintained wound closure, digital photography, and an adverse event assessment.

Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Burns
  • Trauma
  • Venous Ulcers
  • Device: MIST Therapy
    Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
    Other Names:
    • MIST
    • MIST Treatment
  • Other: Standard of care
    Standard of care provided per site-specific protocol
    Other Name: Standard wound care
  • Experimental: MIST Therapy in conjunction with SOC
    Low-frequency, non-contact ultrasound administered in conjunction with standard of care treatment
    Intervention: Device: MIST Therapy
  • Active Comparator: Control arm
    Standard of care treatment
    Intervention: Other: Standard of care
Prather JL, Tummel EK, Patel AB, Smith DJ, Gould LJ. Prospective Randomized Controlled Trial Comparing the Effects of Noncontact Low-Frequency Ultrasound with Standard Care in Healing Split-Thickness Donor Sites. J Am Coll Surg. 2015 Aug;221(2):309-18. doi: 10.1016/j.jamcollsurg.2015.02.031. Epub 2015 Mar 14.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2014
July 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subject of any race and at least 18 years old
  • Subject requires skin grafting
  • Subject's wound must be between 20 cm2 and 200 cm2
  • Subject's wound presents with no clinical signs of acute infection
  • Subject has ahd no prior MIST Therapy to the enrolled wound
  • Subject or subject's legally authorized representative understands the nature of the procedure(s) and provides written informed consent prior to study enrollment
  • Subject is willing and able to comply with all specified care and visit requirements
  • Women of childbearing potential must not be pregnant or lactating, and must be using adequate and accepted contraceptive methods
  • Subject has a reasonable expectation of completing the study

Exclusion Criteria:

  • Subject's condition requires the use of topical antibiotics at the time of study enrollment
  • Subject's wound would require ultrasound near an electronic implant or prosthesis, e.g., near or over the heart, or over the thoracic area if the subject is using a cardiac pacemaker
  • Subject is known to be suffering from a disorder or other situation that the subject or investigator feels would interfere with compliance or other study requirements
  • Subject is currently enrolled or has been enrolled in the last 30 days in another investigational device or drug trial
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Celleration, Inc.
Celleration, Inc.
Not Provided
Principal Investigator: Lisa J Gould, M.D.,Ph.D James A. Haley Veterans Hospital
Principal Investigator: David Smith, MD University South Florida
Celleration, Inc.
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP